Your browser doesn't support javascript.
loading
Tumor xenograft modeling identifies an association between TCF4 loss and breast cancer chemoresistance.
Ruiz de Garibay, Gorka; Mateo, Francesca; Stradella, Agostina; Valdés-Mas, Rafael; Palomero, Luis; Serra-Musach, Jordi; Puente, Diana A; Díaz-Navarro, Ander; Vargas-Parra, Gardenia; Tornero, Eva; Morilla, Idoia; Farré, Lourdes; Martinez-Iniesta, María; Herranz, Carmen; McCormack, Emmet; Vidal, August; Petit, Anna; Soler, Teresa; Lázaro, Conxi; Puente, Xose S; Villanueva, Alberto; Pujana, Miguel Angel.
Afiliação
  • Ruiz de Garibay G; Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Catalonia, Spain.
  • Mateo F; Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Catalonia, Spain.
  • Stradella A; Department of Medical Oncology, ICO, Oncobell, IDIBELL, L'Hospitalet del Llobregat, Barcelona 08908, Catalonia, Spain.
  • Valdés-Mas R; Department of Biochemistry and Molecular Biology, Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo, Oviedo 33006, Spain.
  • Palomero L; Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Catalonia, Spain.
  • Serra-Musach J; Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Catalonia, Spain.
  • Puente DA; Department of Biochemistry and Molecular Biology, Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo, Oviedo 33006, Spain.
  • Díaz-Navarro A; Department of Biochemistry and Molecular Biology, Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo, Oviedo 33006, Spain.
  • Vargas-Parra G; Hereditary Cancer Programme, ICO, Oncobell, IDIBELL, L'Hospitalet del Llobregat, Barcelona 08908, Catalonia, Spain.
  • Tornero E; Hereditary Cancer Programme, ICO, Oncobell, IDIBELL, L'Hospitalet del Llobregat, Barcelona 08908, Catalonia, Spain.
  • Morilla I; Department of Medical Oncology, ICO, Oncobell, IDIBELL, L'Hospitalet del Llobregat, Barcelona 08908, Catalonia, Spain.
  • Farré L; Chemoresistance and Predictive Factors Laboratory, ProCURE, ICO, Oncobell, IDIBELL, L'Hospitalet del Llobregat, Barcelona 08908, Catalonia, Spain.
  • Martinez-Iniesta M; Chemoresistance and Predictive Factors Laboratory, ProCURE, ICO, Oncobell, IDIBELL, L'Hospitalet del Llobregat, Barcelona 08908, Catalonia, Spain.
  • Herranz C; Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Catalonia, Spain.
  • McCormack E; Departments of Clinical Science and Internal Medicine, Haematology Section, Haukeland University Hospital, and Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen 5021, Norway.
  • Vidal A; Department of Pathology, University Hospital of Bellvitge, Oncobell, IDIBELL, L'Hospitalet del Llobregat, Barcelona 08908, Catalonia, Spain.
  • Petit A; Department of Pathology, University Hospital of Bellvitge, Oncobell, IDIBELL, L'Hospitalet del Llobregat, Barcelona 08908, Catalonia, Spain.
  • Soler T; Department of Pathology, University Hospital of Bellvitge, Oncobell, IDIBELL, L'Hospitalet del Llobregat, Barcelona 08908, Catalonia, Spain.
  • Lázaro C; Hereditary Cancer Programme, ICO, Oncobell, IDIBELL, L'Hospitalet del Llobregat, Barcelona 08908, Catalonia, Spain.
  • Puente XS; Biomedical Research Networking Centre of Cancer, CIBERONC, Spain.
  • Villanueva A; Department of Biochemistry and Molecular Biology, Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo, Oviedo 33006, Spain.
  • Pujana MA; Biomedical Research Networking Centre of Cancer, CIBERONC, Spain.
Dis Model Mech ; 11(5)2018 05 18.
Article em En | MEDLINE | ID: mdl-29666142
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Resistencia a Medicamentos Antineoplásicos / Fator de Transcrição 4 Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Animals / Female / Humans Idioma: En Revista: Dis Model Mech Assunto da revista: MEDICINA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Espanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Resistencia a Medicamentos Antineoplásicos / Fator de Transcrição 4 Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Animals / Female / Humans Idioma: En Revista: Dis Model Mech Assunto da revista: MEDICINA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Espanha